Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...

Cirtuvivint is a selective pan-CLK, pan-DYRK inhibitor that modulates alternative RNA splicing, including transcripts involved in oncogenic pathways. Preclinical studies have shown that CLK/DYRK ...

Since then, the program has funneled millions of dollars to thousands of early-career doctors and professors who are ...

The first-in-human clinical phase I trial assessing the feasibility and safety of WDVAX, an immunostimulatory ...

At the same time as more and more young people are affected by mental illness, the need for research in psychology and ...

The cuts to the National Institutes of Health will cost lives, harm our economy and curtail America's leadership in the world ...

University of Maryland School of Medicine Dean Mark T. Gladwin, MD, along with University of Maryland Medical Center (UMMC) ...

Out of more than 300 applicants, Ayudando Latinos a Soñar (ALAS) was selected as one of only five organizations in the U.S. to receive a prestigious $200,000 national research grant from the Robert ...

Rules that allow for this expanded scope without requiring physician collaboration vary by state. Currently in the US, 27 ...

ROURKELA: The National Institute of Technology-Rourkela has secured two research projects under the Scheme for Promotion of Academic and Research Collaboration ...

Cancer Research UK's Centre for Drug Development is sponsoring and conducting the phase I/II clinical trial of ALETA-001, the lead agent in Aleta Biotherapeutics' portfolio. Additional clinical trial ...

University of Maryland School of Medicine Dean Mark T. Gladwin, MD, along with University of Maryland Medical Center (UMMC) President Bert O'Malley, MD, today announced the appointment of C. David ...